Modulating Wnt Signaling Pathway to Enhance Allograft Integration in Orthopaedic Trauma Treatment
Annual rept. 30 Sep 2011-29 Sep 2012
RUSH UNIV MEDICAL CENTER CHICAGO IL
Pagination or Media Count:
The research project was designed to test a novel approach of modulating Wnt signaling pathway in the bone tissue repair by using monoclonal antibodies against sclerostin Sost and DKK-1 donated by Amgen Inc., Thousand Oaks, CA under MTA. Since the previous annual report, the project has progressed at a rapid pace. After overcoming the technical issue with allograft placement, we have performed all the surgical procedures, harvested approximately 85 of the test material remaining will be completed by mid-December 2012, analyzed approx. 10 of the samples by mu CT data presented in this report, banked the remaining samples. The initial assessment of the data is encouraging as it reveals that the use of anti-Sost or anti-Dkk-1 antibodies enhances new bone formation around the allograft. The mechanical testing the regenerated region has not been performed but likely to support our hypothesis of improved integration.
- Anatomy and Physiology
- Medicine and Medical Research